Currently, most HER2+ breast cancer patients are treated with anti-HER2 therapies, and because a substantial fraction of treated patients later suffers distant relapse relapses due to therapy resistance, we sought to determine the relationship between PPP2R2B expression and therapeutic outcome. This evidence concerns the gene ERBB2 and breast carcinoma.